Skip to main content
PMC home page
BMC Public Health logoLink to BMC Public Health
. 2018 May 22;18:645. doi: 10.1186/s12889-018-5555-x

Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation

Henshaw Uchechi Okoroiwu 1,✉, Ifeyinwa Maryann Okafor 1, Enosakhare Aiyudubie Asemota 1, Dorathy Chioma Okpokam 1
PMCID: PMC5964952  PMID: 29788937

Abstract

Background

Provision of constant and safe blood has been a public health challenge in Sub-Saharan Africa with high prevalence of transfusion-transmissible infections (TTIs). This study was aimed at determining the trend and seroprevalence of HBV, HCV, syphilis and HIV across the years within study among prospective blood donors at blood bank in University of Calabar Teaching Hospital (UCTH), Calabar, Nigeria.

Methods

A retrospective analysis of blood donor data from January 2005 to December 2016 was conducted in Blood Bank/Donor Clinic of University of Calabar Teaching Hospital, Calabar, Nigeria. Sera samples were screened for hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus (HCV), human immunodeficiency virus (HIV) 1 and 2 and Treponema pallidum using commercially available immunochromatic based kits.

Results

Out of the 24,979 screened prospective donors in the 2005–2016 study period, 3739 (14.96%) were infected with at least one infective agent. The overall prevalence of HBV, HCV, syphilis and HIV were 4.1, 3.6, 3.1 and 4.2%, respectively. During the period of study, the percentage of all transfusion-transmissible infections declined significantly with remarkable decline in HIV. The study showed male dominated donor pool (98.7%) with higher prevalence (4.2%) of transfusion-transmissible infections than in female donors (0.0%). Commercial donors constituted majority (62.0%) of the donors and as well had the highest prevalence of transfusion-transmissible infections. Majority (62.9%) of the donors were repeat donors.

Conclusion

HBV, HCV, syphilis and HIV have remained a big threat to safe blood transfusion in Nigeria and Sub-Saharan Africa at large. Strict adherence to selection criteria and algorithm of donor screening are recommended.

Keywords: Blood donors, HBV, HCV, HIV, TTI, Blood donors in Calabar

Background

Blood transfusion can be a lifesaving intervention. However, like all treatments, it may result in acute or delayed complications and carries the risk of transfusion-transmissible infections such as HIV, hepatitis B and C, syphilis, malaria, etc. as well as hemolysis [1, 2]. Blood safety remains a major public health problem in Sub-Saharan Africa owing to inadequacies of national blood transfusion policies and services, appropriate infrastructures, qualified personnel and financial resources [3]. Nigeria established a national blood transfusion policy through a published set of guidelines in December 2006 which gave birth to the National Blood Transfusion Service. The national blood policy is essentially made up of sets of action plans which are geared towards the provision of safe, available and affordable blood donor units. It is structured into the following strata: the national blood transfusion service (NBTS), the zonal blood service centers, state and local government areas blood service centers, the armed forces blood service centers, private and other nongovernmental health establishments [4, 5]. Despite these efforts, in Nigeria, there is still lack of political will and open-mindedness to innovative ways to improve supply and safety of blood through voluntary donors [6]. Transfusion-transmissible infections remain one of the most serious complications of blood transfusion [7]. Transfusion of infected blood is the cause of 5–10% of HIV infection in Sub-Saharan Africa [8] and 12.5% of the patients who received blood transfusions are at risk of post-transfusion hepatitis [9].

The 2015 global prevalence of HBV infection in general population as reported by World Health Organization [10] was 3.5% accounting for about 257 million persons. Prevalence was highest in Western Pacific (6.2%) and Africa (6.1%). Eastern Mediterranean region, South East Asia region, European region, and Regions of Americas had 3.3, 2.0, 1.6 and 0.7% prevalence, respectively [10]. More so, the Polaris Observatory Collaborators in a survey using 128 countries reported mean global HBV prevalence of 4.9% with China, India, Nigeria, Indonesia, and the Philippines accounting for more than 57% of all the HBsAg positive cases [11].

The 2015 global prevalence of HCV as reported by WHO estimated that 71 million persons were living with HCV infection in the world accounting for 1% of the population. Of these, the highest prevalence were recorded in the Eastern Mediterranean region (2.3%) and European region (1.5%). African region, Regions of Americas, Western Pacific region and South East Asia region had 1.0, 0.7, 0.7 and 0.5% prevalence, respectively [10].

Globally, 36.7 million people were living with HIV at the end of 2016. An estimated 0.8% of adults aged 15–45 years worldwide are living with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. Sub-Saharan Africa remains the most severely affected with nearly 1 in every 25 adults (4.2%) living with HIV and accounting for nearly two-third of people living with HIV worldwide [12].

The global incidence of syphilis was 25.1 case per 100,000 adult population among the 55 countries that reported in the GARPR (Global Aids Response Progress Reports) in 2014 [13]. Each year, there are about 5.6 million people living with syphilis [14].

Only continuous and strict implementation of donor selection, screening tests and effective inactivation procedures can ensure the elimination, or at least reduction of the risk of acquiring transfusion-transmissible infections [15].

Assessment of data on the prevalence of transfusion transmissible infections among blood donors permits evaluation of the occurrence of infections in the blood donor population and consequently, the safety of the collected donations. It also gives an idea of the epidemiology of the transfusion-transmissible infections in the study community [16].

Methods

A retrospective analysis of blood donor data from January 2005 to December 2016 was conducted in Blood Bank/Donor Clinic of University of Calabar Teaching Hospital, Calabar, Nigeria. The donors were within 18–65 years of age and weighed not less than 50 kg. Within the study period 24,979 apparently healthy prospective donors were tested for HBsAg, HCV, VDRL (syphilis) and HIV. Tests were performed using commercially available kits according to the manufacturers’ instructions. HCV and HBsAg screening were done using serum/plasma rapid immunochromatographic kits developed by ABON Biopharm (Hangzhou) Co. limited. The HIV status of the donors were determined using two rapid HIV test methods; Determine™ HIV 1/2 (Alere Medical Co. Ltd., Japan) and Uni-Gold™ Recombigen® HIV 1/2 (Trinity Biotech, Ireland) test kits. Sera from all donors were tested for the presence of treponemal antibodies using ACON rapid immunochromatographic VDRL (ACON Laboratories, Inc., San Diego, CA, USA) kits following the manufacturer’s instructions. The algorithm used in the blood bank assessed is detailed in Fig. 1.

Fig. 1.

Fig. 1

Open in a new tab

Algorithm for serological screening for blood donors

Results

The overall number of prospective donors screened for donation within 2005–2016 period was 24,979 comprising of 24,654 (98.70%) males and 325 (1.30%) females. Of these, 1013 (4.1%) were reactive for HBsAg, 896 (3.6%) for HCV, 786 (3.6%) for syphilis and 1044 (4.2%) for HIV (Table 1). The total number of those infected with at least one agent was 3739. The percentage prevalence of transfusion transmissible infection in the study period was 14.96% while the percentage prevalence of HBV, HCV, Syphilis and HIV infected donors were 4.1, 3.6, 3.1 and 4.2%, respectively (Table 1). The year-to-year fluctuations in the overall prevalence of TTI in the prevalence of all the infections were all statistically significant (Table 1).

Table 1.

Transfusion-transmissible infections in blood donors at University of Calabar Teaching Hospital during the period of 2005–2016

Year No. of blood donors screened Prevalence
HBV HCV Syphilis HIV
N. % N. % N. % N. %
2005 1410 79 5.6 58 4.1 54 3.8 81 5.7
2006 1871 82 4.4 108 5.8 80 4.2 103 5.5
2007 2110 94 4.5 48 2.3 76 3.6 121 5.7
2008 2118 98 4.6 52 2.5 44 2.1 80 3.7
2009 2225 115 5.1 25 1.1 83 3.7 152 6.8
2010 2327 77 3.3 61 2.6 83 3.6 124 5.3
2011 3234 121 3.7 272 8.4 183 5.7 118 3.6
2012 2008 81 4.0 67 3.3 78 3.9 59 2.9
2013 1611 60 3.7 30 1.9 15 0.9 96 6.0
2014 1883 77 4.1 79 4.2 43 2.3 57 3.0
2015 2178 60 2.8 39 1.8 9 0.4 18 0.8
2016 2004 69 3.4 57 2.8 38 19 35 1.7
Total 24,979 1013 4.1 896 3.6 786 3.6 1044 4.2
P value X2(11) N = 32.153, P = 0.001 X2(11) = 316.068, P <  0.01 X2(11) N = 171.003, P <  0.01 X2(11) N = 182.261, P <  0.01
Gender
Male 24,654 (98.70) 1012 4.1 896 3.6 786 3.2 1044 4.2
Female 325 (1.30) 1 0.3 0 0 0 0 0 0
Open in a new tab

N absolute number of positive blood donors, % percentage of positive blood donors, P significance of year-to-year fluctuations, determined by chi square test, HBV Hepatitis B virus, HCV Hepatitis C virus, HIV Human Immunodeficiency Virus

Within the study period, a declining trend in prevalence of TTI-positivity among donors was observed which was the result of decreasing number of HBV, HCV, syphilis and HIV positive donors (Table 1).

There were 137 (0.5%) voluntary, 9355 (37.5%) family replacement and 15,487 (62.0%) commercial donors in this study. There was no significant difference in the trend of donors over the years (Fig. 2). Transfusion transmissible infection was observed in 3 (2.2%) of the voluntary donors; consisting of 2 (1.5%), 1 (0.7%) and 0 (0%) HBsAg, HCV, Syphilis and HIV reactive cases, respectively. The family replacement donors had 1160 (12.4%) TTIs frequency consisting of 303 (3.2%), 253 (2.7%) and 387 (4.1%) reactive cases of HBsAg, HCV, Syphilis and HIV, respectively. More so, 15,487 (62.9%) cases of TTIs consisting of 708 (4.6%), 642 (4.1%), 569 (3.7%) and 657 (4.2%) cases of HBsAg, HCV, Syphilis and HIV, respectively were observed in the commercial donors (Table 2). There were 9267 (37.1%) first time and 15,712 (62.9%) repeat donors in this study (Table 3).

Fig. 2.

Fig. 2

Open in a new tab

Blood donation pattern over the period of 2005–2016 in University of Calabar Teaching Hospital, Nigeria

Table 2.

Prevlence of Transfusion-transmissible infections in the three blood donor categories

Donor Category Total Number of Samples (%) Number of Positive Cases (%) Total TTI (%)
HBV (%) HCV (%) Syphilis (%) HIV (%)
Voluntary Donors 137 (0.5) 2 (1.5) 1 (0.7) 0 (0.00) 0 (0.00) 3 (2.2)
Replacement Donors 9355 (37.5) 303 (3.2) 253 (2.7) 217 (2.3) 387 (4.1) 1160 (12.4)
Commercial Donors 15,487 (62.0) 708 (4.6) 642 (4.1) 569 (3.7) 657 (4.2) 15,487 (62.9)
P value X2(2) =743.4 X2(2) =698.3 X2(2) =157.6 X2(2) =69.8 X2(2) = 26,808
P<  0.01 P<  0.01 P<  0.01 P<  0.01 P<  0.01
Open in a new tab

Table 3.

Categorization of blood donors based on frequency of blood donation

Donor Category Frequency %
First time 9267 37.1
Repeat 15,712 62.9
Open in a new tab

Discussion

This study recorded the overall prevalence of various transfusion-transmissible infections in prospective blood donors at the blood bank of University of Calabar Teaching Hospital, Nigeria in the period from 2005 to 2016. Within the study period, we found that 14.96% (n = 3739) of the prospective donors were positive for transfusion-transmissible infections (TTIs). The decreasing trend in the prevalence of TTI observed in this study is in line with the global trend resulting from improved control of sexually transmitted infections [17], introduction of mandatory screening for TTI and launching of intervention programmes [18, 19]. Our finding is lower than another study in Nigeria [20] and Burkina Faso [21] that had 19.3 and 19.3%, respectively, but higher than earlier report from Ethiopia [22] with 11.5%. The difference in the prevalence may be due to differences in health care system in the different study settings as well as varying magnitude of risk factors for contracting transfusion transmissible infections [22] in the various settings.

In this study the prevalence of HBV was 4.1%. This value is lower than 14.3, 11.1, 26.0 and 20.3% reported in Jos [23], Kano [20], Taraba [24] and Ibadan [25], respectively in similar studies within Nigeria. However, lower value (1.67%) has been reported in Portharcourt [26], Nigeria. Similar findings have been reported in other Sub-Sahara African countries. The prevalence of HBV found in this study in Calabar Nigeria is similar to 4.7% reported in Ethiopia [22], while same is lower than 11.59, 7.51, 11.2 and 14.96% reported in Ghana [27], Benin [28], Cameroon [29] and Burkina Faso [30], respectively. Prevalence of hepatitis B observed in this study could be ranked low when compared with other Sub Sahara African countries and regions in Nigeria.

The prevalence of HCV in this study was 3.6%. This value is similar to 3.4 and 4.1% reported in Kano [30] and Benue [31], respectively. However, this finding is higher than 0.5 and 2.0% reported in Portharcourt [32] and Nnewi [33], respectively but lower than 6.1 and 6.0% reported in Jos [34] and Oshogbo [35] respectively, being studies within Nigeria. Comparatively with some Sub-Saharan regions, similar values; 3.2 and 4.4% have been reported in Kenya [36] and Ghana [37], respectively. However, lower value (0.4%) have been reported in Ethiopia [22] whereas higher value (8.6%) has been reported in Burkina Faso [21]. The reason for the relatively lower rate of seroprevalence of HBV and HCV in this study compared with other studies is unclear, but could be ascribed to differences in methodology, sensitivity and specificity of the various rapid test kits used in the different studies. The improvement in technology might make current screening reagents to be more specific and reliable, and could also be a pointer that there are geographical differences in prevalence.

The overall prevalence of syphilis in this study was 3.1%. The value obtained from this study is similar to 3.6 and 2.61% reported in Maiduguri [38] and Ile Ife [39], respectively within Nigeria. However, lower value of 0.1% has been reported in Portharcourt [26]. Similar result has been reported from Sub-Saharan region such as Burkina Faso [21] (3.96%). However, lower values have been reported in Ethiopia [22] (0.1%) and Kenya [36] (1.2%) whereas a higher value of 7.5% has been reported in Ghana [40]. The reason for the disparity in the prevalence of syphilis observed in this study when compared to other studies may be due to geographical differences in the prevalence of syphilis as well as methodological differences. It has been earlier reported that T. pallidum particle agglutination assay are more sensitive than rapid plasma reagin and T. pallidum hemagglutination assay [3].

Seroprevalence of HIV in this study was 4.2%. This prevalence is similar to 4.6 and 3.8% reported in similar Nigerian studies in Sokoto [41] and Kano [42]. However, lower values of 1 and 2.8% have been reported in Portharcourt [26] and Kaduna [43]. Data from some other Sub-Saharan region has reported similar result in Ghana [37] (4.9%). However, lower values of 0.1 and 2.21% have been reported in Ethiopia [22] and Burkina faso [21], respectively. Though the overall HIV prevalence in this study is high, there was a sharp decline in the prevalence across the years from a score of 5.7% in the starting year to 1.7% in the ending year. The earlier rise in HIV seroprevalence observed in this study corresponds to the peak of HIV epidemic at the era when HIV was not recognized as public health concern. This was also when people were in denial of the disease. The subsequent decline that ensued could be interpreted as the outcome of the various intervention programmes that have been implemented over the years.

This study observed significantly declining trend of transfusion-transmissible infections within the period under study. This observation is in consonance with reported decline in HIV seroprevalence in Nigeria [26, 42]. This trend gives credence to much of the HIV/AIDS intervention programmes launched over the years.

There was a male dominated donor pool (98.70%) in this study. This demographic pattern have been replicated in earlier studies from other parts of Nigeria [44, 45]. Similar trend has been reported in India (95.20%) [46], Pakistan (99.62%) [47], Cameroon (82.0%) [48], Ethiopia (86.8%) [49] and Mexico (81.86%) [50]. This observation could be attributed to the cultural dogma that women should abstain from blood donation as they do lose blood monthly via menstruation. More so, the present study and the studies with similar trends were comprised mostly of replacement and remunerated donors. Male donors have been reported to be motivated by altruism and remuneration benefits [51]. However, this observation was at variance with reports from United States of America (51.7%) [52], Spain (54.0%), Portugal (57.0%), Belgium (54.6%), Netherlands (50.0%,), Denmark (50.0%), France (50.0%), United Kingdom (47.0%) and Finland (45.0%) [51] where the values were almost at par in both sexes. This non gender difference may be attributed to the fact that majority of the blood donations in these developed countries were voluntary donations which is mainly driven by altruism which is shared by both sexes [51]. Females have been reported to be motivated to donate mainly by altruism rather than males who do for both altruism and remuneration benefits [51]. Male donors recorded the highest prevalence of TTIs. This finding is similar to the report of Okocha et al. [44]. Zaheer et al. [47] attributed this to the view that women are confined to home settings, and therefore, are comparatively less exposed to the risks factors associated with transfusion transmissible infections as compared to males.

This study identified commercial donors as the predominant donor type, followed by the family replacement donors, while the voluntary donors were the least in number. The amount of voluntarily donated blood has continued to fall over the years in Nigeria due to logistics and organizational problems associated with the national blood transfusion service. The net result is that commercial blood donation becomes the order of the day. This finding is in consonance with previous reports [35, 44]. However, the finding is at variance with previous report by Damulak et al. [53] in Jos. This disparity could be attributed to the fact that the study in Jos was carried out in the National Blood Transfusion Service Center whereas our study was done in a hospital based blood bank. Blood drive for voluntary blood donation is a regular practice in national blood transfusion centers in Nigeria unlike hospital based blood banks that rely mostly on walk in voluntary donors. Commercially remunerated blood donors recorded the highest prevalence of TTIs, while voluntary donors had the least. This finding further corroborates the earlier suggestion by World Health Organization (WHO) that voluntary donors are less likely to transmit transfusion transmissible-infection than family replacement and commercial donors [54]. An individual in desperate financial need is less likely to reveal his/her actual health status and the monetary reward could make it appealing to high risk donors.

A larger part (62.9%) of donors in this study were repeat donors. This is owing to the fact that majority of the donors were commercial donors. Commercial donors are more likely to repeat because of the financial remuneration that is intended to motivate it.

Limitations of study

The rapid kits used for this study are in vitro qualitative methods. The quantitative values cannot be determined by these screening tests. A negative result at any time does not preclude the possibility of latent infection as most of the test kits were antibody based (HCV, HIV and syphilis) and surface antigen based (HBV). The essence of the pre-donation screening is to determine deferment status; hence, the algorithm is direct except for HIV that has three steps. However for logistics reasons, all HIV screening in this study were benched at UNIGOLD (second stage). More so, the borderline between family replacement and commercial donors is gray as sometimes patient relatives may recruit commercial donors and present same as replacement on their own.

Conclusion

The present study clearly showed a high prevalence of transfusion-transmissible infection among blood donors in the studied population. The high remunerated blood donor pool and male dominated donor population call for renewed attention to donor recruitment in blood transfusion centers in the country and also consistent enlightenment programmes on transfusion-transmissible infections with a view of reversing this trend. There is a need for stringent selection of blood donors with the emphasis on getting voluntary donations and comprehensive screening of donors for TTIs.

Acknowledgments

Funding

This study was funded by the authors.

Availability of data and materials

Datasets generated and analysed in this study are available from the corresponding author on reasonable request.

Abbreviations

HBsAg

Hepatitis B surface antigen

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

TTIs

Transfusion-transmissible infections

VDRL

Venereal disease research laboratory

Authors’ contributions

HUO conceived the study, analysed data, did statistical analysis and prepared the manuscript; IMO analysed data and prepared the manuscript; EAA analysed data and prepared the manuscript; DCO anlysed data and prepared the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by Health Research Ethical Committee (HREC) of the University of Calabar Teaching Hospital. As only secondary data was used in this study, consent to participate was not required.

Competing interests

The authors declare no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Henshaw Uchechi Okoroiwu, Phone: +234 8038833901, Email: okoroiwuhenshaw@gmail.com.

Ifeyinwa Maryann Okafor, Email: okaforify12@gmail.com.

Enosakhare Aiyudubie Asemota, Email: nosa35asemota@gmail.com.

Dorathy Chioma Okpokam, Email: oghalove@gmail.com.

References

  • 1.Nilima S, Sawke GK, Chawla S. Seroprevalence of common transfusion-transmitted infections among blood donors. Peoples J Sci Res. 2010;3:5–7. [Google Scholar]
  • 2.Okafor MI, Akpotuzor JO, Ibanga IA. Prevalence of alpha and Beta Haemolysin antibodies among transfused adults in Nigeria. J Med Lab Sci. 2010;19:27–31. [Google Scholar]
  • 3.Tessema B, Yismaw G, Kassu A, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University teaching hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis. 2010;10:111. doi: 10.1186/1471-2334-10-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Aneke JC, Okocha CE. Blood transfusion safety; current states and challenges in Nigeria. Asian J Tranfus Sci. 2017;11(1):1–5. doi: 10.4103/0973-6247.200781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.National Blood Transfusion Service . Federal Ministry of Health Nigeria. The National Blood Policy. Nigeria: National Blood Transfusion Service Ministry of Health; 2006. [Google Scholar]
  • 6.Erhabor O, Adias TC, Mainasara AS. Provision of safe blood transfusion services in low income setting in West Africa, case study of Nigeria. Adv Med Biol. 2013;59:1–58. [Google Scholar]
  • 7.Barbara J, Eglin R. Introduction: transfusion-transmitted infection, then and now. In: Barbara J, Regan F, Contreras M, editors. Transfusion microbiology. New York: Cambridge University Press; 2008. pp. 1–7. [Google Scholar]
  • 8.Safe Blood for Africa foundation. WHO fact sheet 2014. Available at: http://www.safebloodforafrica.org/index.php/sbfa. Accessed 28 Jan 2018.
  • 9.Fasola FA, Otegbayo IA. Post-transfusion hepatitis in sickle cell anemia retrospective-prospective analysis. Niger J Clin Pract. 2002;5:16–19. [Google Scholar]
  • 10.World Health Organization (WHO). Global hepatitis report 2017. Geneva: World health Organization. p. 2017.
  • 11.The Polaris Observatory Collaborators. Global prevalence, treatment and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 10.1016/52468-1253(18)30056-6. [DOI] [PubMed]
  • 12.World Health Organization (WHO). Global Health Observatory (GHO) data: HIV/AIDS. Available at: http://www.who.int/gho/hiv/en/. Accessed 11 April 2018.
  • 13.World Health Organization (WHO). Report on global sexually transmitted infection surveillance 2015. Geneva: World health Organization. p. 2015.
  • 14.World Health Organization (WHO). Sexually transmitted infections (STIs) 2016 fact sheet. Available at: http://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis). Accessed 11 April 2018.
  • 15.Tiwari BR, Ghimmire P, Karki S, et al. Seroprevalence of human immunodeficiency virus in Nepalese blood donors: a study from three regional blood transfusion services. Asian J Transfus Sci. 2008;2:66–68. doi: 10.4103/0973-6247.42663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jasmin J, Vaidehi P, Kaushik B, et al. Seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital. Int J Biol Med Res. 2012;3:1423–1425. [Google Scholar]
  • 17.World Health Organization. Report on global sexually transmitted infection surveillance 2013. Geneva: WHODocument Production Services; 2014.
  • 18.O’Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmissible infections in donations made to Canadian blood services. Transfusion. 2007;47:316–325. doi: 10.1111/j.1537-2995.2007.01108.x. [DOI] [PubMed] [Google Scholar]
  • 19.National Agency for the Control of Aids (NACA). HIV counseling and testing. Available at: https://naca.gov.ng/hct-hiv-counseling-and-testing/. Accessed 28 Jan 2018.
  • 20.Nwankwo E, Momodu I, Umar I, Musa B, Adeleke S. Seroprevalence of major blood-borne infections among blood donors in Kano, Nigeria. Turk J Med. 2012;42:337–341. [Google Scholar]
  • 21.Nagalo MB, Sanou M, Bisseye C, Kaboré MI, Nebie YK, Kienou K. Seroprevalence of human immunodeficiency virus, hepatitis B and C virus and syphilis among blood donors in Koudougou (Burkina Faso) in 2009. Blood Transfus. 2011;9:419–424. doi: 10.2450/2011.0112-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yusuf M, Alemayehu B. Seroprevalence of transfusion transmitted infection among blood donors of Jijiga blood bank, East Ethiopia; retrospective 4 years study. BMC Res Notes. 2016;9:129. doi: 10.1186/s13104-016-1925-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis- B surface antigen among blood donors and immunodeficiency virus-infected patients in Jos Nigeria. Mem Inst Oswaldo Cruz. 2005;100:13–16. doi: 10.1590/S0074-02762005000100002. [DOI] [PubMed] [Google Scholar]
  • 24.Elkanah OS, Okoye AL, Debby-Sambo OE. Prevalence of hepatitis-B surface antigen among blood donors in Jalingo, Taraba state, Nigeria. Niger J Parasitol. 2013;34:119–122. [Google Scholar]
  • 25.Otegbayo JA, Fasola FO, Abja A. Prevalence of hepatitis-B surface antigen (HBsAg) and hepatitis B envelop antigen (HBeAg), risk factor of vital acquisition and serum transaminase among blood donors in Ibadan, Nigeria. Trop Gastroenterol. 2003;24:196–197. [PubMed] [Google Scholar]
  • 26.Ejele OA, Ojule AC. The prevalence of hepatitis-B surface antigen (HBsAg), among prospective donors and patients in Portharcourt, Nigeria. Niger J Med. 2004;13:336–338. [PubMed] [Google Scholar]
  • 27.Julius TD, Sylvanus K, Ireneous NS, Asebga PN, Ziem JB, Sagoe K. Prevalence of hepatitis B virus infection among blood donors at the tamale teaching hospital Ghana 2009. BMC Res Notes. 2012;5:115. doi: 10.1186/1756-0500-5-115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Takpo JB, Sam O, Diarra-Nama AJ. Status of blood safety in the WHO African region: report on the 2004 survey. Brazzaville Republic of the Congo: AFRO WHO; 2007.
  • 29.Julius MN, Patrick AN, Michel K, et al. Prevalence of hepatitis B virus infection among blood donors at the Younde military hospital, Cameroon. Microbiol Res Int. 2016;4:6–10. [Google Scholar]
  • 30.Bala JA, Kawo AH, Muktar MD, Sarki A, Magaji N, Aliyu IA, et al. Prevalence of hepatitis C infection among blood donors in some selected hospitals in Kano, Nigeria. Intern Res J Microbiol. 2012;3:21722. [Google Scholar]
  • 31.Nwannadi IA, Alao O, Shoaga L. Hepatitis C among blood donors in teaching hospital in north Central Nigeria. IOSR J Dental Med Sci. 2014;13:20–23. [Google Scholar]
  • 32.Erhabor O, Ejele OA, Nwanche CA. The risk of acquired hepatitis C virus infection among blood donors in Portharcourt: the question of blood safety in Nigeria. Niger J Clin Pract. 2006;9:18–21. [PubMed] [Google Scholar]
  • 33.Odenigbo C, Oguejiolor C, Okonkwo U, Asamugha A, Ezeh T, Okocha E. Prevalence of antibodies to hepatitis C virus in blood donors in Nnewi, south East Nigeria: in association with blood groups. Intern J Gastroenterol. 2011; 10:5580/1c70
  • 34.Dammulak OD, Piwuna TO. Joseph DE, Ogbenna AA, Kut SD, Godit P, et al. Hepatitis C virus antibody among blood donors: the experience in a Nigerian blood transfusion center. Glo Adv Res J Med Sci. 2013;2:108–113. [Google Scholar]
  • 35.Buseri FI, Muhibi MA, Jeremiah ZA. Seroepidemiology of transfusion transmissible infections among blood donors in Osogbo, south West Nigeria. Blood Transfus. 2009;7:293–297. doi: 10.2450/2009.0071-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kamande MW, Kibebe H, Mokua J. Prevalence of transfusion transmissible infections among blood donated at Nyeri satellite transfusion Centre in Kenya. IOSR J Pharm. 2016;6:20–30. doi: 10.9790/3021-067022025. [DOI] [Google Scholar]
  • 37.Walana W, Ahiaba S, Hokey P, Vicar EK, Acquah SEK, Der EM, et al. Seroprevalence of HIV, HBV and HCV among blood donors in Kintampo municipal hospitals, Ghana. Br Microbiol Res J. 2014;4(12):1491–1499. doi: 10.9734/BMRJ/2014/12160. [DOI] [Google Scholar]
  • 38.Chikwem JO, Mohammed I, Okara GC. Prevalence of transmissible blood infections among blood donors at the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. East Afr Med J. 1997;74:213–216. [PubMed] [Google Scholar]
  • 39.Salawu L, Bolarinwa RA, Adegunloye AB, et al. HBsAg, anti-HCV and VDRL in blood donors: prevalence and trends in the last three and a half years in a tertiary healthcare facility in Ile-Ife, Nigeria. Int J Med Med Sci. 2010;2:335–341. [Google Scholar]
  • 40.Andrew AA, William K, Henry A, et al. Prevalence of antibodies to syphilis among blood donors in Accra, Ghana. Jpn J Infect Dis. 2003;56:165–167. [PubMed] [Google Scholar]
  • 41.Erhabor O, Usman I, Wase A, et al. Prevalence of transfusion-transmissible HIV infection in Sokoto, north western Nigeia. Am J Microbiol Biotechnol. 2014;1:36–42. [Google Scholar]
  • 42.Imoru M, Eke C, Adegoke A. Prevalence of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among blood donors in Kano state, Nigeria. J Med Lab Sci. 2003;12:59–63. [Google Scholar]
  • 43.Hassan A, Muktar HM, Mamman AI, et al. The incidence of HIV among blood donors in Kaduna, Nigeria. Afr Health Sci. 2008;8:60. [PMC free article] [PubMed] [Google Scholar]
  • 44.Okocha EC, Aneke JC, Ezeh TU, Ibeh NC, Nwosu GA, Okorie IO, et al. The epidemiology of transfusion-transmissible infections among blood donors in Nnewi, south-East Nigeria. Afr J Med Health Sci. 2015;14:125–129. doi: 10.4103/2384-5589.170183. [DOI] [Google Scholar]
  • 45.Kassim OD, Oyekale TO, Aneke JC, Durosinmi MA. Prevalence of seropositive blood donors for hepatitis B, C and HIV viruses at the Federal Medical Centre, ado-Ekiti Nigeria. Ann Trop Pathol. 2012;3:47–55. [Google Scholar]
  • 46.Unnikrishnan B, Rao P, Kumar N, Gati S, Prasad R, Armarnath A, et al. Profile of blood donors and reasons for deferral in coastal South India. Australas Med J. 2011;4(7):379–385. doi: 10.4066/AMJ.2011.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Zaheer HA, Saeed U, Waheed Y, Karimi S, Waheed U. Prevalence and trends of hepatitis B, hepatitis C and human immunodeficiency virus among blood donors in Islamabad, Pakistan 2005-2013. J Blood Disorders Transf. 2014;5(6):1–5. [Google Scholar]
  • 48.Noubiap JJ, Joko WY, Nansseu JRN, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C virus and syphilis infections among first time donors in Edea, Cameroon. Int J Infect Dis. 2013;17(10):e832–e837. doi: 10.1016/j.ijid.2012.12.007. [DOI] [PubMed] [Google Scholar]
  • 49.Birhaneselassie M. Prevalence of transfusion transmissible infections in donors in Ethiopian blood bank between 2009 and 2013 and donation factors that would improve the safety of the blood supply in underdeveloped countries. Lab Med. 2016;47(2):134–139. doi: 10.1093/labmed/lmw003. [DOI] [PubMed] [Google Scholar]
  • 50.Alvarado-Esquivel C, Rascon-Careaga A, Liesenfeld O. Seroprevalence and associated risk factors for toxoplasma gondii infection in healthy blood donors; a cross sectional study in senora, Mexico. Biomed Res Int. 2016;9597276:8. doi: 10.1155/2016/9597276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Bani M, Giussani B. Gender differences in giving blood: a review of literature. Blood Transfus. 2010;8:278–287. doi: 10.2450/2010.0156-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Shaz BH, James AB, Hillyer KL, Shrelber GB, Hillyer CD. Demographic patterns of blood donors in and donations in a large metropolitan area. J Natl Med Assoc. 2011;103:351–357. doi: 10.1016/S0027-9684(15)30316-3. [DOI] [PubMed] [Google Scholar]
  • 53.Damulak OD, Bolorunduro SO, Boman F, Bako L. Pattern of blood donors in Jos. Jos J Med. 2011;5(5):44–45. [Google Scholar]
  • 54.World Health Organization (WHO) Blood safety strategy for the African region. Brazzaville: World Health Organization, Regional Office for Africa; 2002. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Datasets generated and analysed in this study are available from the corresponding author on reasonable request.

Articles from BMC Public Health are provided here courtesy of BMC

RESOURCES